Add like
Add dislike
Add to saved papers

Drug Target Prioritization for Alzheimer's Disease Using Protein Interaction Network Analysis.

Alzheimer's disease (AD) is an age-related neurodegenerative disorder that accounts for numerous deaths worldwide. AD is the most common cause of dementia, characterized by accumulation of fibrous amyloid beta protein in the brain with clinical symptoms, such as loss of intellectual and social skills, gradually leading to the death of brain cells. The genetic complexity of AD during disease progression requires a systems-level understanding to design viable therapeutics. We present an integrative computational analysis to prioritize AD-associated genes outlined through a protein-protein interaction network. Multiple topological parameters of the network were considered to target proteins which are accountable for disease susceptibility. Furthermore, in silico protein structure modeling and molecular dynamics simulation approaches were implemented to characterize presenilin 2 (PSEN2) protein as one of the leading targets in the network. The findings are constructive to aid future drug discovery endeavors in the treatment of AD.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app